Every material Form 8-K UroGen Pharma Ltd. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
UroGen reported third-quarter 2026 revenue of $89.0 million, up from $27.5 million a year earlier, driven by ZUSDURI, and its net loss narrowed to $1.5 million from $33.3 million. The company cut its full-year 2026 JELMYTO net product revenue guidance to approximately $90 million from $97 million to $101 million, which weighs on the outlook for that product.
Total Q3 2026 revenue was $89.0 million versus $27.5 million in Q3 2025; ZUSDURI net product revenue was $68.0 million, up 35% from Q2 2026.
JELMYTO Q3 2026 net product revenue was $21.0 million, down from $25.7 million in Q3 2025, including a one-time unfavorable adjustment of approximately $1.5 million.
Net loss was $1.5 million, or $0.03 per share, versus a $33.3 million loss, or $0.69 per share, a year earlier.
Full-year 2026 JELMYTO guidance was cut to approximately $90 million; full-year operating expense guidance of $260 million to $270 million was unchanged.
UroGen Pharma's U.S. subsidiary obtained an exclusive option to license IntraGel Therapeutics' TumoCure product and hydrogel delivery platform for advanced head and neck cancer, plus options on additional products and a research license. The company also agreed to invest up to $7,000,000 in IntraGel's equity securities. The filing does not state financial terms of the option exercise or the size of any future payments.
Agreements dated August 18, 2026 with IntraGel Therapeutics, Ltd., an Israeli company
Exclusive option to obtain worldwide license to TumoCure with SRGel platform for advanced head and neck cancer
Agreed to invest up to $7,000,000 in IntraGel equity under a Securities Purchase Agreement
UroGen reported second quarter 2026 total revenue of $72.5 million, up from $24.2 million a year earlier, driven by the launch of ZUSDURI, and a net loss of $14.4 million, or $0.28 per share, compared with $49.9 million, or $1.05 per share, in the prior-year quarter. The company raised its full-year 2026 operating expense guidance to $260 million to $270 million to accelerate investment in the ZUSDURI launch and pipeline, while keeping its JELMYTO revenue guidance of $97 million to $101 million.
Total revenue of $72.5 million in Q2 2026 vs. $24.2 million in Q2 2025; ZUSDURI net product revenue was $50.4 million and JELMYTO was $22.0 million
Net loss of $14.4 million, or $0.28 per basic and diluted share, vs. $49.9 million, or $1.05 per share, a year earlier
Full-year 2026 operating expense guidance raised to $260 million to $270 million, including $20 million to $24 million of non-cash share-based compensation
Cash, cash equivalents and marketable securities totaled $108.0 million as of June 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every UroGen Pharma Ltd. filing is on SEC EDGAR ↗. 8-K briefs of other companies →